This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giannoulis, M. G. Articles by Umpleby, A. M. Search for Related Content PubMed PubMed Citation Articles by Giannoulis, M. G. Articles by Umpleby, A. M. Related Collections Neuroendocrinology and Pituitary Male Endocrinology Metabolism

The Effects of Growth Hormone and/or Testosterone on Whole Body Protein Kinetics and Skeletal Muscle Gene Expression in Healthy Elderly Men: A Randomized Controlled Trial

Departments of Diabetes and Endocrinology (M.G.G., N.J., F.S.-M., P.H.S., A.M.U.) and Elderly Care and Acute Medicine (F.C.M.), Division of Medicine King’s College London, St. Thomas’s Hospital London, London, United Kingdom SE1 7EH; and Division of Endocrinology (K.S.N.), Mayo Clinic College of Medicine, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: Margot Umpleby, Diabetes and Endocrinology, Postgraduate Medical School University of Surrey, Daphne Jackson Road, Manor Park Guildford GU2 7WG, United Kingdom. E-mail: m.umpleby{at}surrey.ac.uk.

Context: Alterations of protein turnover may contribute to the progressive decline of muscle mass with aging.

Objective: Our objective was to examine the effects of near-physiological recombinant human GH and/or testosterone (T) administration to older men on whole body protein kinetics and muscle gene expression.

Design, Settings, and Participants: A 6-month randomized, double-blind, placebo-controlled trial in 21 healthy elderly men aged 65–75 yr, was performed. Participants were randomized to receive placebo GH and placebo T, rhGH and placebo T (GH), T and placebo GH (T), or rhGH and T (GHT).

Interventions: The leucine rate of appearance (index of proteolysis), nonoxidative leucine disposal rate (an index of protein synthesis), and leucine oxidation rate were measured with an infusion of L-[1-¹³C] leucine. Muscle biopsies for the measurement of gene expression were performed. Body composition and aerobic capacity (maximal oxygen capacity) were measured.

Results: Serum IGF-I levels increased significantly with GH and GHT (P < 0.001) compared with placebo. T increased significantly only in the T group (P = 0.028). Leucine rate of appearance and nonoxidative leucine disposal rate increased with GH (P = 0.015, P = 0.019) and GHT (P = 0.017, P = 0.02), but leucine oxidation did not change significantly in any treatment group. Midthigh muscle mass and maximal oxygen capacity increased (P < 0.04) with GHT only. Expression of muscle function genes did not change significantly, but the within-group comparisons revealed a significant increase of androgen receptor expression in the GHT group (P = 0.001).

Conclusion: This study showed that 6-month treatment with low-dose GH alone or with T in healthy elderly men produces comparable increments in whole body protein turnover and protein synthesis.

This article has been cited by other articles:

				M. Pires-Oliveira, A. L. G. C. Maragno, L. T. Parreiras-e-Silva, T. Chiavegatti, M. D. Gomes, and R. O. Godinho Testosterone represses ubiquitin ligases atrogin-1 and Murf-1 expression in an androgen-sensitive rat skeletal muscle in vivo J Appl Physiol, February 1, 2010; 108(2): 266 - 273. [Abstract] [Full Text] [PDF]

				N. Moller and J. O. L. Jorgensen Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects Endocr. Rev., April 1, 2009; 30(2): 152 - 177. [Abstract] [Full Text] [PDF]

				G. C. Henderson, K. Dhatariya, G. C. Ford, K. A. Klaus, R. Basu, R. A. Rizza, M. D. Jensen, S. Khosla, P. O'Brien, and K. S. Nair Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements FASEB J, February 1, 2009; 23(2): 631 - 641. [Abstract] [Full Text] [PDF]